Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on August 4, 2014. The filing announces the company's financial and operating results for the quarter ended June 30, 2014. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the filing text itself.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of results for the quarter ended June 30, 2014.
Guidance, Outlook, and Risks
The filing text does not include management commentary, guidance, outlook, or specific risk factors. It serves solely as a notification that the results have been announced via a press release. The filing includes a standard disclaimer stating that the information in the press release is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the attached Exhibit 99.1 (Press Release), as they are not listed in the 8-K text.
- Confirm the company name is PharmAthene, Inc., noting the discrepancy with the "Altimmune, Inc." label in the request metadata.
- Review the press release for any updates on clinical trial progress or regulatory milestones, which are typical for this biotechnology sector.
- Check subsequent filings for any restatements or updates to the June 30, 2014 results.